Dimethyltryptamine (DMT): a biochemical Swiss Army knife in neuroinflammation and neuroprotection?

Szabo and colleagues frame the paper within an inflammatory theory of neuropsychiatric and neurodegenerative disorders, noting that dysregulated innate immune responses and microglial activation contribute to conditions such as schizophrenia, bipolar disorder, depression and Alzheimer’s disease. Pattern recognition receptors on tissue-resident immune cells detect damage-associated or pathogen-associated molecular patterns, activating intracellular signalling cascades that include nuclear factor kappaB (NF-κB), a master transcriptional regulator of inflammatory cytokines and chemokines. The introduction highlights the importance of Th1 and Th17 adaptive responses in chronic central nervous system inflammation and outlines how GPCR-linked systems—particularly serotonin/5-hydroxytryptamine receptors (5-HTRs) and the sigma-1 receptor (Sig-1R)—can modulate immune signalling, calcium homeostasis and unfolded protein responses in ways that influence inflammation, cell survival and neuronal differentiation. This perspective proposes that N,N-dimethyltryptamine (DMT), an endogenous tryptamine with affinity for multiple 5-HT receptor subtypes and for Sig-1R, may act as a multifaceted regulator of inflammation and a promoter of neuroprotection and regeneration. The authors set out to synthesise biochemical and physiological evidence for DMT’s capacity to regulate NF-κB and MAPK pathways via G-protein-coupled receptor cross-talk, to attenuate pro-inflammatory cytokine and chemokine release, and to inhibit Th1/Th17 activation. They frame DMT as a potential therapeutic lead for a broad range of chronic inflammatory, autoimmune and neurodegenerative conditions, while noting that its strong hallucinogenic effects present a challenge for drug development.

Szabo and colleagues interpret the assembled evidence as indicating multiple mechanisms by which DMT could modulate neuroinflammation and confer neuroprotection. They emphasise that DMT acts as an agonist at several 5-HT receptor subtypes (including 5-HT1A, 5-HT2A and 5-HT2C) and at the Sig-1R, a molecular chaperone located at the mitochondrion-associated endoplasmic reticulum membrane (MAM). Sig-1R activity is discussed as important for calcium regulation, cellular energetics and the mitigation of unfolded protein responses; through these actions Sig-1R agonism can reduce intracellular calcium-driven cell death signalling and promote neuronal survival under stress. At the intracellular signalling level, the paper highlights probable cross-talk between GPCR-coupled pathways and canonical inflammatory cascades. Specific G-protein subunits (Gα families Gi and Gq, and Gβγ) are proposed to couple 5-HTRs and Sig-1R activity to PLC-β–IP3–calcium release, protein kinase C (PKC) activation, PI3K/Akt signalling and the IκB kinase-dependent regulation of NF-κB. Such interactions could either stimulate or inhibit NF-κB and MAPK pathway kinetics depending on receptor and G-protein context, thereby shaping the spatio-temporal pattern of cytokine and chemokine release. The authors describe two major anti-inflammatory scenarios in the brain: first, modulation of microglial cytokine production that favours anti-inflammatory mediators such as IL-10 and TGFβ; second, direct or indirect suppression of NF-κB and MAPK signalling in immune cells, leading to attenuated chemokine and pro-inflammatory cytokine signalling. Empirical lines of evidence presented in the perspective include reports that DMT can suppress inflammatory cytokine and chemokine release from dendritic cells and inhibit Th1 and Th17 differentiation or activation. The paper also draws parallels with selective Sig-1R agonists such as PRE084 and cutamesine, which in prior in vitro and in vivo studies promoted neuronal survival, regeneration and increased levels of glial cell-derived neurotrophic factor (GDNF). From these points, Szabo and colleagues suggest that endogenous DMT could facilitate transport to and binding at Sig-1R sites in the brain and thereby contribute to neuroregenerative processes. The authors acknowledge key uncertainties. They note that the precise physiological role of endogenous DMT remains unestablished and that the hallucinogenic properties of DMT pose a substantive obstacle for therapeutic use. Limitations in the evidence base are implicit in the perspective format—direct clinical-data or controlled trial evidence for DMT as a therapeutic agent in human neuroinflammatory or neurodegenerative disease is not presented in the extracted text. Future drug development, the paper argues, will need to reconcile DMT’s putative immunoregulatory and neuroprotective activities with the challenge of minimising or separating its psychotropic effects.